Pharma Focus Asia

CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease

Thursday, May 24, 2018

CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S (CPH: ORPHA) to improve the lives of patients and families living with neuronopathic Gaucher disease, a rare, inherited, progressive and debilitating lysosomal storage disorder.

Under the terms of the agreement, CENTOGENE is supporting Orphazyme’s clinical trial efforts in India for the use of the small molecule, arimoclomol, for the treatment of neuronopathic Gaucher disease.

“Being able to monitor the treatment improvement in a clinical trial is a crucial capability for the pharmaceutical industry today. With our deep expertise in biomarker identification and development of diagnostic tools combined with our profound rare disease knowledge and global reach, we are ideally positioned to be the partner of choice for Orphazyme and drug developers worldwide,” said Dr. Arndt Rolfs, CEO and founder of CENTOGENE.

CENTOGENE is responsible for processing and analyzing a variety of different sample types from patients participating in the trial including plasma, cerebral spinal fluid and dried blood spots from CENTOGENE’s CentoCard®. Furthermore, CENTOGENE has developed and is using the most sensitive and validated biomarker for Gaucher disease, lysoGb1, as a monitoring tool during the trial.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024